banner

Brightcove Shares Nosedive on Weak 2013 Guidance

Brightcove (BCOV)

Coming up on its one-year anniversary of being a public entity, shares of Brightcove, Inc. (NASDAQ: BCOV) printed all-time lows after delivering its fourth-quarter and full 2012 year earnings and a weak outlook for 2013.

The provider of cloud-based video streaming services reported total revenue for the fourth quarter of 2012 of $24.3 million, an increase of 31 percent compared to $18.5 million for the fourth quarter of 2011. Gross profit for the fourth quarter of 2012 was $16.7 million, compared to $12.9 million for the fourth quarter of 2011. Excluding items, adjusted net loss totaled $1.5 million, or 5 cents per share, compared to a net loss of $2.7 million, or 53 cents per share in the year prior quarter.

Revenue and net loss actually beat the expectations of Wall Street analysts, whom were calling for revenue of $23.2 million and a net loss of 7 cents per share.



What wiped the luster off the stock was the company’s 2013 guidance. Brightcove said that it expects an adjusted net loss in the range of 18 cent to 25 cents per share and revenue between $102 million and $105 million.

Analysts were only expecting a loss of 13 cents per share and revenue of $106 million.

Keeping things upbeat, Brightcove chairman and chief executive* Jeremy Allaire said in a corporate statement, “Brightcove ended 2012 on a strong note, with our fourth quarter results once again exceeding our revenue and profitability guidance.” Why the asterisk, you may ask? Because Brightcove also announced that Allaire has resigned as CEO and that Chief Operating Officer David Mendels is assuming the Allaire’s position on March 31. At that time, Allaire will become the Executive Chairman of the Board.

Meanwhile, Accel Partners’ James Breyer resigned from the Brightcove board, the company said today.

For the complete 2012 year, total revenue for Brightcove was $88.0 million, an increase of 38 percent compared to $63.6 million for 2011. Gross profit was $60.6 million for 2012, compared to $43.3 million for 2011. Non-GAAP gross profit was $61.2 million for 2012, representing a year-over-year increase of 41 percent. Excluding items, adjusted net loss for 2012 was $8.3 million, or 34 cents per share, compared to an adjusted net loss of $13.4 million, or $2.74 per share in 2011.

Share of BCOV debuted February 17 at $14.50 per share. After a run to highs of $25.43 at the end of March, shares have been steadily bleeding-out value since, closing Thursday at $8.42. Shares plunged with the guidance today, dropping to close down by 27.4 percent at $6.11 after establishing a new record low at $5.97.

Brightcove (BCOV) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Hearing Date Set in Blue Calypso Lawsuit Against LivingSocial

Hearing Date Set in Blue Calypso Lawsuit Against LivingSocial(0)

Blue Calypso Inc. (OTCBB: BCYP), an innovator in digital social advertising, mobile content syndication, and analytics, recently announced a Markman hearing set for August 27, 2013 in its patent infringement case against LivingSocial. Findings from this hearing may encourage settlements or provide insight into the likelihood of a particular outcome. With the success seen by

Digital Development Group Partners with Hollywood Bad Boy Charlie Sheen

Digital Development Group Partners with Hollywood Bad Boy Charlie Sheen(0)

One might think that celebrity endorsements would be fantastic for the share price of a small or microcap company. After all, famous and successful athletes or movie stars have a stack of cash to invest and the connections to help accelerate business developments. Oddly, though, it doesn’t seem to have a great deal of impact.

Sunvalley Solar Shares Rise from Bottom on Solar Installation Contract

Sunvalley Solar Shares Rise from Bottom on Solar Installation Contract(0)

Shares of Sunvalley Solar, Inc. (OTCBB: SSOL) are rising in trading Monday morning after the solar power technology company disclosed a new contract to 87.5-kilowatt solar system installation contract from Corporate Logistics in City of Industry, California. The contract is for a system capable of generating 131,146 kilowatt hours of electrical power each year, utilizing

Men’s Health Features Naked Brand Group Line of Underwear

Men’s Health Features Naked Brand Group Line of Underwear(0)

Naked Brand Group, Inc. (OTCQB: NAKD) said Friday that its Naked Boxer Brief has been selected by Men’s Health for its online guide, “Affordable Spring Style Guide 100 under $100.”  The guide was published on MensHealth.com on March 20.  This is the second time the company has been featured in the men’s mag in as

Sunshine Biopharma Meeting with CMOs to Manufacture Drug for Breast Cancer Trials

Sunshine Biopharma Meeting with CMOs to Manufacture Drug for Breast Cancer Trials(0)

Sunshine Biopharma Inc. (OTCQB: SBFM) reported on Thursday that it is in negotiations with Contract Manufacturing Organizations, or CMOs, as the next progression towards the anticipated clinical trials of its flagship cancer drug, Adva-27a, against multi-drug resistant forms of breast cancer. The trials are scheduled to be hosted by the leading cancer center Jewish General

read more
banner


Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.